Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cingulate Inc
(NQ:
CING
)
10.27
+0.58 (+5.99%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cingulate Inc
< Previous
1
2
3
4
5
6
Next >
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
June 20, 2023
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740.
Via
Benzinga
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
June 08, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Why Cingulate Shares Are Trading Higher Today
February 24, 2023
Via
Benzinga
Cingulate to Present at 13th Annual LD Micro Invitational
May 25, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Partnership By Biotech Firm Could Be Big News For The Commercialization Of Its Innovative ADHD Drug Candidate
May 18, 2023
Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ: CING), and Tim Moore, Senior VP of Biotech of Indegene, were recently guests on Benzinga’s All Access.
Via
Benzinga
Cingulate, Indegene to Participate in Benzinga All Live Access Event
May 12, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
May 10, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
May 03, 2023
Scalable Supply of CTx-1301 Ready to be Produced with Cingulate on Track to Meet Previously Announced Clinical Timelines for Phase 3 Trial Program
From
Cingulate Inc.
Via
GlobeNewswire
Cingulate: This Novel Drug Technology May Soon Relieve A Patient's "Pill-Burden"
April 20, 2023
Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ: CING), was recently a guest on Benzinga’s All-Access.
Via
Benzinga
Cingulate to Participate in Benzinga All Live Access Event
April 14, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
April 04, 2023
From
Cingulate Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 14, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 14, 2023
Via
Benzinga
Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 14, 2023
Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a...
Via
Benzinga
Why PacWest Bancorp Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket
March 14, 2023
Gainers PacWest Bancorp (NASDAQ: PACW) rose 29.9% to $12.66 in pre-market trading after multiple insider buys by Officers, Directors reported late Monday.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
March 13, 2023
Via
Benzinga
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 13, 2023
Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.
Via
Benzinga
5 Short Squeeze Candidates To Watch: Ambrx Biopharma, Kala Pharmaceuticals And This Company That Moved Up 1,403 Positions
March 13, 2023
Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 13, 2023
Via
Benzinga
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
March 13, 2023
Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of...
Via
Benzinga
Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301
March 13, 2023
From
Indegene Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
March 10, 2023
Via
Benzinga
Cingulate Inc. (NASDAQ: CING) Featured in Coverage of the 35th Annual Roth Conference
February 28, 2023
Via
Investor Brand Network
Tesla, Amazon, Union Pacific, Woodside Energy, Cingulate: Why These 5 Stocks Drawing Investors' Attention Today
February 26, 2023
Via
Benzinga
Dow Dips 350 Points; S&P 500 Down Over 1%
February 24, 2023
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 300 points on Friday. The Dow traded down 1.07% to 32,798.91 while the NASDAQ fell 1.90% to 11,370.53. The S&P 500...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 24, 2023
Via
Benzinga
Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 24, 2023
Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday.
Via
Benzinga
Nasdaq Tumbles 2%; Timber Pharmaceuticals Shares Spike Higher
February 24, 2023
U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 450 points on Friday. The Dow traded down 1.39% to 32,692.94 while the NASDAQ fell 2.14% to 11,342.36. The S&P 500 also...
Via
Benzinga
Why Is Nektar Therapeutics (NKTR) Stock Down 39% Today?
February 24, 2023
Nektar Therapeutics (NKTR) stock is taking a beating on Friday following the release of poor Phase 2 clinical trial data.
Via
InvestorPlace
Why Is SELLAS Life Sciences (SLS) Stock Down 38% Today?
February 24, 2023
SELLAS Life Sciences (SLS) stock is falling on Friday after the biopharmaceutical company announced a proposed public offering.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.